Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
D. Lucas Kerr, Franziska Haderk, Trever G. Bivona
Topics & Concepts
Allosteric regulationDruggabilityCancer researchReceptor tyrosine kinaseMAPK/ERK pathwayKinaseTumor microenvironmentBiologyReceptorCell biologyBiochemistryTumor cellsGeneProtein Tyrosine PhosphatasesGalectins and Cancer BiologyCytokine Signaling Pathways and Interactions